Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology firm, announced participation in the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. CEO Gail McIntyre and CMO Reshma Rangwala will engage in a virtual fireside chat, with the presentation available on November 22, 2021, at 10:00 AM ET. The company will also hold virtual one-on-one meetings on December 1, 2021. Aravive is focused on developing targeted therapeutics for life-threatening cancers, currently evaluating its lead therapeutic, batiraxcept, in multiple trials.
- None.
- None.
HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 – December 2, 2021. Aravive’s presentation will be available for viewing on November 22, 2021 at 10:00 AM ET. Aravive will also participate in virtual one-on-one meetings on December 1, 2021.
This conference is being held virtually, and a live webcast will be accessible on the Events & Presentations page of www.aravive.com. An archived replay of the webcast will be available for 90 days following the webcast.
About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers. The Company is currently evaluating its lead therapeutic, batiraxcept (AVB-500), in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.
Contacts:
Investors:
Luke Heagle, Real Chemistry
lheagle@realchemistry.com
(910) 619-5764
Media:
Aulani Capuchin, Real Chemistry
acapuchin@realchemistry.com
(559) 355-2673
FAQ
When will Aravive present at the Piper Sandler Healthcare Conference?
Who from Aravive will participate in the virtual fireside chat?
What is Aravive's lead therapeutic being evaluated?
When is Aravive's one-on-one meeting during the conference?
What is the focus of Aravive's clinical research?
How can I access Aravive's conference webcast?
